Advertisement
Advertisement

BNGO

BNGO logo

Bionano Genomics, Inc. Common Stock

1.28
USD
Sponsored
+0.07
+5.79%
Apr 15, 15:59 UTC -4
Closed
exchange

After-Market

1.25

-0.03
-2.03%

BNGO Earnings Reports

Positive Surprise Ratio

BNGO beat 11 of 30 last estimates.

37%

Next Report

Date of Next Report
May 12, 2026
Estimate for Q1 26 (Revenue/ EPS)
$6.77M
/
-$0.76
Implied change from Q4 25 (Revenue/ EPS)
-14.88%
/
+2433.33%
Implied change from Q1 25 (Revenue/ EPS)
+4.81%
/
-33.91%

Bionano Genomics, Inc. Common Stock earnings per share and revenue

On Mar 23, 2026, BNGO reported earnings of -0.03 USD per share (EPS) for Q4 25, beating the estimate of -1.42 USD, resulting in a 97.90% surprise. Revenue reached 7.95 million, compared to an expected 8.01 million, with a -0.74% difference. The market reacted with a -0.63% price change (close before vs. close after earnings).
Looking ahead to Q1 26, 5 analysts forecast an EPS of -0.76 USD, with revenue projected to reach 6.77 million USD, implying an increase of 2433.33% EPS, and decrease of -14.88% in Revenue from the last quarter.

Industry Peers’ Earnings

Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.

logo
Lexaria Bioscience Corp. Common Stock
Report Date
Apr 13, 2026 For Q2 26
Estimate
-$0.09
Actual
-$0.06
Surprise
+38.08%
logo
Sunshine Biopharma Inc.
Report Date
Apr 03, 2026 For Q4 25
Estimate
-$0.27
Actual
-$0.54
Surprise
-96.08%
logo
Pharvaris N.V. Ordinary Shares
Report Date
Apr 02, 2026 For Q4 25
Estimate
-$0.63
Actual
-$0.72
Surprise
-13.69%
logo
Innate Pharma S.A. ADS
Report Date
Apr 01, 2026 For Q1 26
Estimate
-$0.12
Actual
-$0.55
Surprise
-353.80%
FAQ
For Q4 2025, Bionano Genomics, Inc. Common Stock reported EPS of -$0.03, beating estimates by 97.9%, and revenue of $7.95M, -0.74% below expectations.
The stock price moved down -0.63%, changed from $1.59 before the earnings release to $1.58 the day after.
The next earning report is scheduled for May 12, 2026.
Based on 5 analysts, Bionano Genomics, Inc. Common Stock is expected to report EPS of -$0.76 and revenue of $6.77M for Q1 2026.
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement